2 results
Approved WMOCompleted
Primary Study ObjectiveTo assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via registered intramuscular (IM) injection…
Approved WMOCompleted
The purpose of this study is to investigate how quickly and to what extent JNJ-64417184 is absorbed and eliminated from the body when it is given together with drugs that reduce the stomach acidity. The study also investigates how safe the new…